US biotech tycoon opens Africa's first end-to-end Covid-19 jab plant - Capital Business
Connect with us

Hi, what are you looking for?

Employees in clean room clothes work on the production of Pfizer/BioNTech's Comirnaty Covid-19 vaccine at the Allergopharma plant in Reinbek near Hamburg, northern Germany, on April 30, 2021, amid the novel coronavirus / COVID-19 pandemic. (Photo by Christian Charisius / POOL / AFP)

Africa

US biotech tycoon opens Africa’s first end-to-end Covid-19 jab plant

Cape TownSouth Africa, Jan 19 – US biotech billionaire Patrick Soon-Shiong on Wednesday opened a plant in Cape Town that will be the first in Africa to produce Covid-19 vaccines from start to finish.

The factory should churn out its first vials of second-generation coronavirus vaccine “within the year” and produce a billion doses annually by 2025, said Soon-Shiong.

The plant will be South Africa’s third Covid vaccine manufacturing facility but the first in the continent to make the formula across every stage, rather than producing it from semi-finished batches.

Africa currently manufactures less than one percent of all vaccines administered on the continent, according to the World Health Organization (WHO).

South African President Cyril Ramaphosa, speaking at the inaugural event, hailed the plant as a sign of African self-reliance.

“Africa should no longer be the last in line to access vaccines against pandemics, African should no longer go cap in hand to the Western world begging and begging for vaccines,” said Ramaphosa.

“We will stand on our own,” he vowed.

He thanked Soon-Shiong, a South African-born and now United States-based doctor-turned-entrepreneur — for returning “home” to invest in vaccine production.

Born in South Africa to Chinese parents and now a US citizen, the billionaire said the launch was “one of the momentous moments of my life — this is a homecoming.”

Advertisement. Scroll to continue reading.

He made a fortune by inventing a cancer drug and then founded NantWorks, a California-based startup in healthcare, biotech, and artificial intelligence, in 2007.

Production at the state-of-the-art vaccine manufacturing campus will be a collaborative effort between NantWorks, South African research institutions, and four local universities.

“We have now developed this SN (spike nucleic) T-cell vaccine, a second-generation vaccine, and we want to manufacture this in Africa, for Africa, and export it to the world,” said Soon-Shiong.

Advertisement

More on Capital Business

Aviation

NAIROBI, Kenya, Nov 9 – Kenya and South Africa are in consultation to form a Pan-African airline to rival established players such as the...

Kenya

NAIROBI, Kenya, Nov 9 – Kenyans will enjoy visa-free entry to South Africa starting January 1 2023 for a maximum of 90 days annually....

Africa

Nairobi, Kenya, Nov 24 –  Kenya’s national carrier, Kenya Airways PLC (KQ), has signed a Strategic Partnership Framework today with South African Airways (SAA),...